You are here

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Last updated on November 16, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-20 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT03709680
Pfizer
Not yet recruiting
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
NCT03709680
All Genders
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Phase 1 Study To Evaluate The Safety And Pharmacokinetics Of Palbociclib (Ibrance (Registered)) In Combination With Irinotecan And Temozolomide In Pediatric Patients With Recurrent Or Refractory Solid Tumors
This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order to estimate the maximum tolerated dose. Pharmacokinetics and efficacy of palbociclib in combination with chemotherapy will be evaluated.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
The study will be conducted of 3 parts: a dose escalation part (following a rolling 6 design), a dose expansion part, and if applicable, tumor-specific expansion part.

Masking: None (Open Label)
Primary Purpose: Treatment

  • Solid Tumors
  • Ewing Sarcoma
  • Rhabdoid Tumor
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Medulloblastoma
  • Drug: Palbociclib
    Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2 on days 1-14 of a 21-day cycle
    Other Name: Ibrance
  • Drug: Temozolomide
    Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
  • Drug: Irinotecan
    Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Experimental: Single Arm
Palbociclib in combination with temozolomide and irinotecan
Interventions:
  • Drug: Palbociclib
  • Drug: Temozolomide
  • Drug: Irinotecan
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
100
Same as current
July 6, 2023
December 24, 2019   (Final data collection date for primary outcome measure)

Inclusion:

  1. For dose escalation part: Histologically confirmed solid tumor (including CNS tumors but not lymphomas).
  2. For dose expansion cohort: Histologically confirmed solid tumor including but not limited to Ewing sarcoma, rhabdoid tumor, rhabdomyosarcoma, neuroblastoma, and medulloblastoma.
  3. For tumor-specific cohorts: Histologically confirmed solid tumor including but not limited to rhabdoid tumor, rhabdomyosarcoma, neuroblastoma, and medulloblastoma. Ewing sarcoma is not eligible for tumor-specific cohorts.
  4. Age ?2 and <21 years at the time of study entry.
  5. Lansky performance status ?50% for patients ?12 years of age, or Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2 for patients >12 years of age.
  6. Adequate bone marrow function: Absolute neutrophil count ?1000/mm3; Platelet count ?100,000/mm3 (transfusion independent); Hemoglobin ?8.5 g/dL (transfusion allowed);
  7. Adequate renal function (serum creatinine level based on age/gender must be less than or equal to the maximum upper limits specified in protocol)
  8. Adequate liver function, including:Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × upper limit of normal (ULN) or ?5 × ULN for age, if attributable to disease involvement of the liver; Total bilirubin ?1.5 × ULN for age.
  9. Measurable disease as defined by RECIST version 1.1 or modified RANO criteria for CNS disease.
  10. Recovered to CTCAE Grade ?1, or to baseline, from any non-hematological acute toxicities of prior surgery, chemotherapy, immunotherapy, radiotherapy, differentiation therapy or biologic therapy, with the exception of alopecia.
  11. Serum/urine pregnancy test (for all girls ?8 years of age) negative at screening and at the baseline visit.
  12. Evidence of a personally signed and dated informed consent document indicating that the patient or a legally acceptable representative/parent(s)/legal guardian, for minors, has been informed of all pertinent aspects of the study. Minor study patients also must provide age appropriate assent according to the local guidelines, where applicable.
  13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.

Exclusion:

  1. Prior treatment with a CDK4/6 inhibitor or progression while on treatment with an IRN-containing regimen that includes TMZ. Patients who have received the combination of IRN and TMZ and did not progress while on these medications are eligible.
  2. Prior intolerability to IRN and/or TMZ.
  3. Use of strong cytochrome P450 (CYP) 3A inhibitors or inducers or strong uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) inhibitors within 12 days of Cycle 1 Day 1 (C1D1).
  4. Prior growth factors within 7 days before study entry or peg-filgrastim within 14 days before study entry.
  5. Radiation therapy within 14 days before study entry.
  6. Systemic anti cancer therapy within 2 weeks prior to study entry and 6 weeks for nitrosoureas.
  7. Previous high dose chemotherapy requiring stem cell rescue within 90 days or persistent AE >Grade 1.
  8. Prior irradiation to >50% of the bone marrow.
  9. Participation in other studies involving investigational drug(s) within 2 weeks or 5 half lives, whichever is longer, prior to study entry.
  10. Major surgery within 4 weeks prior to study entry. Surgical biopsies or central line placement are not considered major surgeries.
  11. Known or suspected hypersensitivity to palbociclib, IRN and/or TMZ.
  12. Patients with known symptomatic brain tumors or brain metastases and require steroids, unless they have been on a stable or on a decreasing steroid dose for >14 days.
  13. Patients with previously diagnosed brain metastases are eligible if they have completed their prior treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry for these metastases for at least 14 days post radiation and 4 weeks post-surgery and are neurologically stable.
  14. Hereditary bone marrow failure disorder.
  15. QTc >470 msec.
  16. History of clinically significant or uncontrolled cardiac disease, including: history of or active congestive heart failure; if patient had congestive heart failure resolve and >1 year from resolution, patient will be considered eligible; clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de Pointes); diagnosed or suspected congenital or acquired prolonged QT syndrome; need for medications known to prolong the QT interval; uncorrected hypomagnesemia or hypokalemia because of potential effects on the QT interval; left ventricular ejection fraction <50% or shortening fraction <28%.
  17. Recent or ongoing clinically significant gastrointestinal disorder that may interfere with absorption of orally administered drugs (eg, gastrectomy).
  18. Evidence of serious active or uncontrolled bacterial, fungal or viral infection or known history of hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
  19. Other severe acute or chronic medical or laboratory test abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results, and in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  20. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  21. Fertile male patients and female patients of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 90 after the last dose of investigational product.
Sexes Eligible for Study: All
2 Years to 20 Years   (Child, Adult)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT03709680
A5481092
Not Provided
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now